As already mentioned, recent cancer immunotherapies have targeted the molecules in the tumor microenvironment of immune check point inhibitors including CTLA4 [17, 18, 29-32], PD-1 [29, 33, 34] or ICOS [39]. This evidence concerns the gene CTLA4 and cancer.